Farabegoli F, Barbi C, Lambertini E, Piva R, 2007
These effects occurred at doses comparable to those used in humans for weight loss, not just extreme overdose scenarios
About one-third of semaglutide users and a similar proportion of tirzepatide users retained their weight loss or even continued to lose weight
However, retatrutide shows a higher overall rate of side effects and produces a more pronounced dose-dependent increase in heart rate due to glucagon receptor activation
This basic understanding could provide us with a path to better treating cardiovascular-kidney-metabolic syndrome in patients living with kidney disease. UC Davis coauthors of the study include Brian J
Since both can affect blood sugar levels, taking them together could potentially cause hypoglycemia